Duan Guangxin, Zhang Jingyu, Wei Zhuxin, Wang Ximing, Zeng Jianfeng, Wu Shuwang, Hu Chunhong, Wen Ling
Center for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions Suzhou 215123 China.
Department of Radiology, Suzhou Dushu Lake Hospital, Dushu Lake Hospital Affiliated to Soochow University, Medical Centre of Soochow University Suzhou 215001 Jiangsu China
Nanoscale Adv. 2023 Jul 26;5(16):4240-4249. doi: 10.1039/d3na00254c. eCollection 2023 Aug 8.
The high mortality of breast cancer is closely related to lymph node (LN) metastasis. Sentinel LNs (SLNs) are the first station where tumor cells metastasize through the lymphatic system. As such, achieving precise diagnosis of the early metastatic status of SLNs during surgery is of paramount importance for precision therapy of breast cancer. While invasive SLNs biopsy is the gold standard for evaluating the status of SLNs, its use is often time-consuming and may increase the risk of operation. It is still challenging to develop a means for rapid SLN metastasis diagnosis. Herein, NaGdF:5%Nd@NaLuF rare earth nanoparticles (Gd:Nd-RENPs) with near-infrared-II (NIR-II) fluorescence and magnetic resonance imaging (MRI) properties were fabricated. With the nanoprobe, metastatic SLNs and lymph vessels (LVs) rapidly brighten and can be observed by the NIR-II imaging system, which is totally different from normal LNs and LVs. The remarkable contrast observed NIR-II imaging serves to swiftly delineate metastatic SLNs from normal ones, subsequently guiding precise surgical resection of metastatic LNs in just 10 minutes. Furthermore, the consistency between the results obtained MRI and NIR-II imaging further validates the dependability of this nanoprobe as a diagnostic tool for metastatic SLNs. Additionally, the Gd:Nd-RENPs exhibited good biocompatibility and . In this study, we demonstrated the advantages and prospects of NIR-II imaging for intraoperative early SLN metastasis assessment and shed light on the potential of the dual-modal Gd:Nd-RENPs as a nanoprobe.
乳腺癌的高死亡率与淋巴结(LN)转移密切相关。前哨淋巴结(SLN)是肿瘤细胞通过淋巴系统转移的第一站。因此,在手术过程中实现对SLN早期转移状态的精确诊断对于乳腺癌的精准治疗至关重要。虽然侵入性SLN活检是评估SLN状态的金标准,但其使用通常耗时且可能增加手术风险。开发一种快速诊断SLN转移的方法仍然具有挑战性。在此,制备了具有近红外-II(NIR-II)荧光和磁共振成像(MRI)特性的NaGdF:5%Nd@NaLuF稀土纳米颗粒(Gd:Nd-RENPs)。使用该纳米探针,转移的SLN和淋巴管(LV)会迅速变亮,并可通过NIR-II成像系统观察到,这与正常的LN和LV完全不同。在NIR-II成像中观察到的显著对比度有助于迅速将转移的SLN与正常的区分开来,随后在仅10分钟内指导对转移LN进行精确的手术切除。此外,MRI和NIR-II成像结果之间的一致性进一步验证了这种纳米探针作为转移SLN诊断工具的可靠性。此外,Gd:Nd-RENPs表现出良好的生物相容性。在本研究中,我们展示了NIR-II成像在术中早期SLN转移评估方面的优势和前景,并阐明了双模态Gd:Nd-RENPs作为纳米探针的潜力。